adjuvant chemort for cholangiocarcinoma
play

Adjuvant chemoRT for Cholangiocarcinoma Edgar Ben-Josef, M.D. Eli - PowerPoint PPT Presentation

Adjuvant chemoRT for Cholangiocarcinoma Edgar Ben-Josef, M.D. Eli Glatstein Professor of Radiation Oncology Vice-Chair for Translational Research Rationale for Radiotherapy in CC and Gallbladder Cancer Disease Spread w Direct: a long the


  1. Adjuvant chemoRT for Cholangiocarcinoma Edgar Ben-Josef, M.D. Eli Glatstein Professor of Radiation Oncology Vice-Chair for Translational Research

  2. Rationale for Radiotherapy in CC and Gallbladder Cancer Disease Spread w Direct: a long the biliary tree and radially w Nodal: w Perihilar and periportal nodes w Along the common bile duct to the retropancreaticoduodenal lymph nodes Patterns of First Failure w Local regional failure rates are high w Hilar ~40% w Distal ~25% w Gallbladder ~20-40% w Isolated LRF is ~10-15% 2

  3. Lack of Evidence is not Evidence of Lack (of Effect) w No prospective randomized trials are available that examined the effect of adjuvant radiotherapy. w Numerous retrospective studies of adjuvant therapy have shown mixed results w Horgan et al JCO 2011 • Meta-analysis 20 series • Adjuvant chemotherapy, radiotherapy, or CRT compared with curative-intent surgery alone • IHCC, EHCC, Gallbladder cancer • Twenty studies involving 6,712 patients • Those receiving CT or CRT derived statistically significant benefit (OR, 0.39, 0.61, respectively); No benefit for RT alone. • The greatest benefit for AT was in those with +LN disease (OR, 0.49) and R1 disease (OR, 0.36) 3

  4. Rationale for radiotherapy in cholangiocarcinoma (SEER) EHCC IHCC Shinohara ET, et al. Radiotherapy is associated with improved survival in adjuvant and palliative treatment of IHCC/EHCC. Int J Radiat Oncol Biol Phys. 2008/2009 4

  5. SWOG S0809 Eligibility: • Phase II trial of adjuvant chemo followed by chemoRT • EHCC and GB Cancer • Stage pT2-4 or N+ or R1 • S/P radical resection; performance status 0 to 1 Treatment: • Chemotherapy (gemcitabine and capecitabine x 4 cycles) • Chemoradiation – 45 Gy to regional LNs, 54-59.4 Gy to tumor bed – 3DCRT or IMRT – Concurrent capecitabine 5

  6. SWOG 0809 Results: – 79 patients ○ R0, n = 54; R1, n = 25 ○ Hilar CC 49%, Distal 17%, GBCA, 32% – 2-year OS 65% (67% R0; 60% R1 patients) – Median overall survival was 35 months – Grade 3 and 4 adverse effects were observed in 52% and 11% of patients, respectively (neutropenia 44%) Conclusion: • Well tolerated, efficacious regimen option 6

  7. DFS and Overall Survival by resection margin SWOG 0809 SWOG 0809 Hilar Komaya et.al Komaya et.al Surgery 2018 Surgery 2018 7

  8. Recurrence After Curative Resection of Perihilar CC w 402 patients (R0, n = 340; R1, n = 62) resected 2001- 2012 w Minimal use of adjuvant therapy, mostly in R1 pts Komaya et. Al., Surgery 2018 8

  9. OS and DFS by disease site 9

  10. Gallbladder Cancer Patterns of (first) Failure w 70 patients s/p radical cholecystectomy and LN dissection; T2 or higher w Median F/U 23 months w Locoregional – 41% (isolated LR 19%) w Distant (with or without LR) – 40%) Kim TG., Radiation Oncology J 2017 35(4):359-367 10 10

  11. Adjuvant Chemoradiotherapy is Associated with Improved Survival for Patients with Resected Gallbladder Carcinoma Kim et al., Ann Surg Oncol (2018) 25:255–264 11 11

  12. Conclusions w Locoregional relapse rates are high after curative resection of CC and GB cancer w Adjuvant radiotherapy improves local control and survival • Retrospective reviews, meta analyses, large database analysis, a single phase 2 study (no prospective phase 3 data) w Some adjuvant chemotherapy regimens improve DFS (capecitabine) w One modality does not exclude the other – there is no reason not to use both 12 12

  13. The 15 th Annual Meeting of the International Society of Gastrointestinal Oncology The 2018 Gastrointestinal Oncology Conference

Recommend


More recommend